Literature DB >> 1688888

Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat.

A Remuzzi1, S Puntorieri, C Battaglia, T Bertani, G Remuzzi.   

Abstract

The effect of enalapril on glomerular hemodynamics and permselectivity and on subsequent sclerosis was studied in male MWF/Ztm rats which spontaneously develop proteinuria and glomerular structural damage. Untreated group 1 and enalapril-treated group 2 (50 mg/liter, in the drinking water) underwent micropuncture studies after 2 mo of observation. After the same period of treatment, group 3 (untreated) and group 4 (enalapril treated) were used for determination of whole-kidney function and neutral dextran clearances. Group 5 (untreated) and group 6 (enalapril treated) were followed for an additional 4 mo and used for kidney function and morphological studies. Enalapril significantly lowered systolic blood pressure, which was elevated in untreated groups, and significantly reduced proteinuria (295 +/- 64 vs. 128 +/- 24 mg/24 h by the end of the study). Despite the reduced renal perfusion pressure, whole-kidney glomerular filtration rate was higher in enalapril-treated than in untreated rats (0.96 +/- 0.14 vs. 0.81 +/- 0.10 ml/min, P less than 0.05) as was the single nephron glomerular filtration rate (54 +/- 7.1 vs. 46 +/- 4.0 nl/min, P less than 0.05). The single glomerular afferent plasma flow was comparable in both groups. Enalapril reduced mean glomerular capillary hydraulic pressure from the normal value of 51 +/- 1 mmHg (untreated rats) to a value lower than normal (44 +/- 1 mmHg, P less than 0.001). These hemodynamic changes were associated with a significant reduction in afferent (approximately 23%) and efferent (approximately 26%) arteriolar resistance. The mean ultrafiltration coefficient was two times higher in the enalapril (0.126 +/- 0.027 nl/s per mmHg) than in the untreated group (0.061 +/- 0.023 nl/s per mmHg). The clearance of dextran macromolecules relative to that of inulin was significantly reduced for all molecular sizes studied (26-64 A) in enalapril-treated vs. untreated rats. Theoretical analysis of dextran fractional clearances using a heteroporous model of neutral solute transport across the glomerular capillary wall indicated that enalapril affected glomerular membrane size selective properties, reducing uniformly the radius of hypothetical membrane pores. Enalapril treatment also significantly limited (P less than 0.01) the development of glomerular structural lesions (mean percentage of sclerotic glomeruli was 4.2 +/- 3.5% [treated] vs. 28 +/- 15% [untreated] rats at the end of the study) as well as tubulo-interstitial damage. These results suggest that the protective effect of enalapril on the development of proteinuria and glomerular sclerosis in this model is due to its property of ameliorating size selectivity and hydraulic permeability of the glomerular capillaries.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688888      PMCID: PMC296456          DOI: 10.1172/JCI114470

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  [A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics].

Authors:  J FUHR; J KACZMARCZYK; C D KRUTTGEN
Journal:  Klin Wochenschr       Date:  1955-08-01

2.  Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy.

Authors:  G N Marinides; G C Groggel; A H Cohen; T Cook; R L Baranowski; C Westenfelder; W A Border
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

3.  THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN.

Authors:  H W Smith; N Finkelstein; L Aliminosa; B Crawford; M Graber
Journal:  J Clin Invest       Date:  1945-05       Impact factor: 14.808

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Molecular weight distribution analysis by gel chromatography on Sephadex.

Authors:  K A Granath; B E Kvist
Journal:  J Chromatogr       Date:  1967-05

6.  Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats.

Authors:  J M Pfeffer; M A Pfeffer; E D Frohlich
Journal:  J Lab Clin Med       Date:  1971-12

7.  Macromolecule transport across glomerular capillaries: application of pore theory.

Authors:  W M Deen; M P Bohrer; B M Brenner
Journal:  Kidney Int       Date:  1979-09       Impact factor: 10.612

8.  Glomerular size selectivity in nephrotic rats exposed to diets with different protein content.

Authors:  A Remuzzi; C Battaglia; L Rossi; C Zoja; G Remuzzi
Journal:  Am J Physiol       Date:  1987-08

9.  Focal and segmental glomerular hyalinosis and sclerosis in the rat.

Authors:  J D Elema; A Arends
Journal:  Lab Invest       Date:  1975-11       Impact factor: 5.662

10.  O-phthalaldehyde: fluorogenic detection of primary amines in the picomole range. Comparison with fluorescamine and ninhydrin.

Authors:  J R Benson; P E Hare
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

View more
  38 in total

1.  Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis.

Authors:  Mauro Abbate; Carla Zoja; Marina Morigi; Daniela Rottoli; Stefania Angioletti; Susanna Tomasoni; Cristina Zanchi; Lorena Longaretti; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Imaging of the porous ultrastructure of the glomerular epithelial filtration slit.

Authors:  Elena Gagliardini; Sara Conti; Ariela Benigni; Giuseppe Remuzzi; Andrea Remuzzi
Journal:  J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 10.121

Review 3.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 4.  Management of hypertension in chronic kidney disease.

Authors:  Pasquale Zamboli; Luca De Nicola; Roberto Minutolo; Valerio Bertino; Fausta Catapano; Giuseppe Conte
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

5.  Functional Human Podocytes Generated in Organoids from Amniotic Fluid Stem Cells.

Authors:  Christodoulos Xinaris; Valentina Benedetti; Rubina Novelli; Mauro Abbate; Paola Rizzo; Sara Conti; Susanna Tomasoni; Daniela Corna; Michela Pozzobon; Daniela Cavallotti; Takashi Yokoo; Marina Morigi; Ariela Benigni; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2015-10-29       Impact factor: 10.121

6.  Role of ultrastructural determinants of glomerular permeability in ultrafiltration function loss.

Authors:  Andrea Remuzzi; Sara Conti; Bogdan Ene-Iordache; Susanna Tomasoni; Paola Rizzo; Ariela Benigni; Giuseppe Remuzzi
Journal:  JCI Insight       Date:  2020-07-09

7.  A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.

Authors:  Erica Daina; Paolo Cravedi; Mirella Alpa; Dario Roccatello; Sara Gamba; Annalisa Perna; Flavio Gaspari; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Nephron       Date:  2015-04-21       Impact factor: 2.847

8.  Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention.

Authors:  Daniela Macconi; Mauro Abbate; Marina Morigi; Stefania Angioletti; Marilena Mister; Simona Buelli; Maria Bonomelli; Peter Mundel; Karlhans Endlich; Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

Review 9.  Angiotensin converting enzyme (ACE) inhibitors and renal function. A review of the current status.

Authors:  A L Kamper
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 10.  Update on the use of trandolapril in the management of cardiovascular disorders.

Authors:  Ariel Diaz; Anique Ducharme
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.